Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept for macular oedema secondary to retinal vein occlusion after prior anti-VEGF treatment
ACTRN12617001487303Phase 4Recruiting
- Sponsor
- A/Prof Andrew Chang
- Start
- Jan 2018
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of aflibercept in Vein occlusion (RVO), sponsored by A/Prof Andrew Chang. Primary endpoints: Effectiveness in maintaining retinal thickness on SD-OCT at week 24 and Effectiveness in maintaining best corrected visual acuity at week 24. Started Jan 2018; status: recruiting.
02
Drugs
aflibercept
03
Conditions
Vein occlusion (RVO)
Beyond the preview
Go deeper on ACTRN12617001487303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12617001487303.